Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Christine Fisher

Concepts (255)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
14
2024
255
4.340
 Why?
Brachytherapy
13
2023
120
4.120
 Why?
Endometrial Neoplasms
10
2025
199
2.030
 Why?
Radiotherapy Planning, Computer-Assisted
7
2024
129
1.760
 Why?
Uterine Neoplasms
6
2025
108
1.750
 Why?
Hysterectomy
5
2019
128
1.700
 Why?
Breast Neoplasms
20
2024
2249
1.680
 Why?
Radiosurgery
5
2025
346
1.590
 Why?
Carcinosarcoma
3
2023
21
1.360
 Why?
Neoplasm Recurrence, Local
11
2025
1060
1.040
 Why?
Genital Neoplasms, Female
4
2024
88
1.020
 Why?
Databases, Factual
5
2021
1351
1.000
 Why?
Radiation Oncology
5
2022
83
0.990
 Why?
Neoplasm Staging
18
2025
1377
0.940
 Why?
Radiotherapy, Intensity-Modulated
2
2024
143
0.870
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2017
56
0.780
 Why?
Chemoradiotherapy
4
2019
226
0.760
 Why?
Radiotherapy, Adjuvant
6
2019
218
0.690
 Why?
Healthcare Disparities
2
2018
651
0.690
 Why?
Simulation Training
1
2021
99
0.660
 Why?
Ovarian Neoplasms
1
2025
563
0.630
 Why?
Female
58
2025
73162
0.620
 Why?
Margins of Excision
1
2019
50
0.600
 Why?
Insurance, Health
2
2018
282
0.590
 Why?
Aquaporin 4
1
2019
96
0.590
 Why?
Necrosis
1
2019
244
0.580
 Why?
Aged
26
2025
23798
0.540
 Why?
Antineoplastic Agents, Immunological
1
2019
191
0.520
 Why?
Middle Aged
30
2025
33355
0.520
 Why?
Insurance Coverage
1
2018
228
0.510
 Why?
Carcinoma, Neuroendocrine
1
2016
42
0.510
 Why?
Perioperative Care
1
2018
182
0.500
 Why?
Standard of Care
1
2016
74
0.500
 Why?
Antineoplastic Combined Chemotherapy Protocols
6
2023
1695
0.490
 Why?
Humans
65
2025
137514
0.480
 Why?
SEER Program
6
2021
218
0.470
 Why?
Adenocarcinoma
4
2024
937
0.450
 Why?
Health Plan Implementation
1
2015
140
0.450
 Why?
Survival Rate
7
2019
1980
0.440
 Why?
Medical Errors
1
2015
110
0.440
 Why?
Neoplasms
3
2022
2666
0.440
 Why?
Carcinoma, Ductal, Breast
1
2014
83
0.430
 Why?
Radiotherapy Dosage
5
2023
267
0.430
 Why?
Quality Assurance, Health Care
1
2015
324
0.410
 Why?
Tumor Suppressor Protein p53
3
2023
531
0.400
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1402
0.400
 Why?
Pelvis
1
2013
112
0.390
 Why?
Carcinoma
1
2014
237
0.390
 Why?
Aged, 80 and over
13
2025
7593
0.390
 Why?
Combined Modality Therapy
6
2020
1241
0.380
 Why?
Prostatectomy
1
2012
104
0.370
 Why?
Practice Patterns, Physicians'
2
2018
1312
0.370
 Why?
Receptor, ErbB-2
5
2021
342
0.370
 Why?
Adult
22
2025
37821
0.360
 Why?
Internship and Residency
1
2021
1131
0.360
 Why?
Vulvar Neoplasms
2
2024
13
0.350
 Why?
Carcinoma, Endometrioid
2
2023
50
0.350
 Why?
Mastectomy, Segmental
4
2020
93
0.330
 Why?
Mutation
3
2023
3964
0.320
 Why?
United States
13
2022
14696
0.320
 Why?
Re-Irradiation
2
2020
8
0.300
 Why?
Lymphatic Metastasis
3
2021
351
0.300
 Why?
Cancer Pain
2
2018
28
0.280
 Why?
Prostatic Neoplasms
2
2012
1034
0.260
 Why?
Analgesics, Opioid
3
2021
1002
0.260
 Why?
Treatment Outcome
9
2023
10821
0.260
 Why?
Sarcoma
2
2021
192
0.250
 Why?
Retrospective Studies
14
2024
15628
0.250
 Why?
Medical Oncology
5
2019
290
0.250
 Why?
Mastectomy
3
2020
139
0.240
 Why?
Chemotherapy, Adjuvant
4
2021
392
0.240
 Why?
Neoadjuvant Therapy
2
2018
405
0.230
 Why?
Regression Analysis
2
2019
1029
0.220
 Why?
Consensus
2
2024
685
0.220
 Why?
Stakeholder Participation
1
2025
77
0.220
 Why?
Young Adult
8
2021
13243
0.210
 Why?
Follow-Up Studies
4
2018
5139
0.210
 Why?
Prognosis
6
2023
4031
0.210
 Why?
Papillomavirus Infections
2
2019
331
0.210
 Why?
Adenocarcinoma, Clear Cell
1
2023
14
0.200
 Why?
Positron-Emission Tomography
1
2024
299
0.200
 Why?
Carcinoma, Renal Cell
2
2015
214
0.200
 Why?
Kaplan-Meier Estimate
4
2021
892
0.200
 Why?
Tertiary Care Centers
1
2023
160
0.200
 Why?
Hodgkin Disease
2
2016
139
0.200
 Why?
Hydrocephalus
1
2023
106
0.190
 Why?
Brain Neoplasms
2
2023
1241
0.190
 Why?
Colonic Neoplasms
1
2024
258
0.190
 Why?
Mass Spectrometry
1
2025
741
0.180
 Why?
beta Catenin
2
2023
251
0.180
 Why?
Kidney Neoplasms
2
2015
400
0.170
 Why?
Veterans
2
2022
1461
0.170
 Why?
Cancer Care Facilities
1
2020
38
0.170
 Why?
Benchmarking
1
2021
184
0.170
 Why?
Carcinoma, Squamous Cell
2
2017
683
0.170
 Why?
Gestational Trophoblastic Disease
1
2019
6
0.160
 Why?
High-Throughput Nucleotide Sequencing
1
2023
538
0.160
 Why?
Benzodiazepines
1
2021
153
0.160
 Why?
Magnetic Resonance Imaging
2
2024
3722
0.160
 Why?
Immunohistochemistry
1
2023
1740
0.150
 Why?
Lymph Nodes
1
2021
493
0.150
 Why?
Communication
1
2025
874
0.150
 Why?
Triple Negative Breast Neoplasms
1
2021
202
0.150
 Why?
Referral and Consultation
1
2024
780
0.150
 Why?
Practice Guidelines as Topic
2
2017
1580
0.140
 Why?
Patient Acceptance of Health Care
1
2024
809
0.140
 Why?
Relative Biological Effectiveness
1
2017
4
0.140
 Why?
Pain Management
2
2018
363
0.140
 Why?
Proportional Hazards Models
2
2018
1263
0.140
 Why?
Radiotherapy, Conformal
1
2017
70
0.130
 Why?
Adolescent
5
2019
21555
0.130
 Why?
Machine Learning
1
2021
496
0.130
 Why?
Propensity Score
1
2018
288
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Breast
1
2017
153
0.130
 Why?
Tomography, X-Ray Computed
2
2024
2681
0.130
 Why?
Pancreatic Neoplasms
1
2024
943
0.120
 Why?
Logistic Models
2
2018
2064
0.120
 Why?
Antineoplastic Agents
3
2017
2145
0.120
 Why?
Radiotherapy Setup Errors
1
2015
3
0.120
 Why?
Radiation Injuries
1
2017
147
0.120
 Why?
Neoplasms, Second Primary
1
2016
115
0.120
 Why?
Neoplasm Grading
4
2019
308
0.120
 Why?
Quality Control
1
2015
171
0.120
 Why?
Medically Uninsured
1
2015
129
0.120
 Why?
Risk Reduction Behavior
1
2016
220
0.120
 Why?
Curriculum
1
2021
980
0.110
 Why?
Physicians
1
2023
904
0.110
 Why?
Radiation Tolerance
1
2015
98
0.110
 Why?
Checklist
1
2015
94
0.110
 Why?
Drug Administration Schedule
1
2016
784
0.110
 Why?
Soft Tissue Neoplasms
1
2015
116
0.110
 Why?
Risk Factors
6
2020
10356
0.110
 Why?
Clinical Competence
1
2021
1093
0.110
 Why?
Cancer Vaccines
2
2005
173
0.110
 Why?
Breast Neoplasms, Male
1
2013
28
0.110
 Why?
Internet
1
2018
656
0.110
 Why?
Case-Control Studies
2
2019
3546
0.110
 Why?
Quality of Life
1
2025
2870
0.100
 Why?
Tumor Burden
1
2014
311
0.100
 Why?
Skin Neoplasms
2
2024
853
0.100
 Why?
Gene Expression Profiling
2
2017
1770
0.100
 Why?
Guideline Adherence
1
2017
549
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1465
0.100
 Why?
Neoplasm Invasiveness
1
2014
510
0.100
 Why?
Bone Neoplasms
1
2015
250
0.100
 Why?
Socioeconomic Factors
1
2017
1286
0.100
 Why?
Patient Safety
1
2015
305
0.090
 Why?
Biomarkers, Tumor
4
2023
1279
0.090
 Why?
DNA Polymerase II
2
2023
38
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
36
0.090
 Why?
Texas
1
2012
246
0.090
 Why?
Medicaid
1
2015
436
0.090
 Why?
Peptide Fragments
2
2005
708
0.090
 Why?
Male
12
2024
67718
0.090
 Why?
Registries
1
2018
2021
0.080
 Why?
Disease Management
1
2014
625
0.080
 Why?
Lung Neoplasms
1
2023
2494
0.080
 Why?
Quality Indicators, Health Care
2
2022
310
0.080
 Why?
Age Factors
1
2017
3301
0.080
 Why?
Cohort Studies
3
2021
5730
0.080
 Why?
Liver Neoplasms
1
2015
786
0.080
 Why?
Survival Analysis
1
2012
1320
0.080
 Why?
Melanoma
1
2015
758
0.070
 Why?
Risk Assessment
2
2020
3439
0.070
 Why?
Opioid-Related Disorders
3
2021
510
0.070
 Why?
Fertility Preservation
2
2019
49
0.070
 Why?
Epidemics
2
2018
87
0.070
 Why?
Medicare
2
2021
747
0.060
 Why?
Prospective Studies
4
2023
7598
0.060
 Why?
Gynecology
2
2018
178
0.060
 Why?
Prevalence
1
2012
2719
0.060
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2005
152
0.060
 Why?
Prostate-Specific Antigen
1
2005
161
0.060
 Why?
Paget Disease, Extramammary
1
2024
4
0.060
 Why?
Radiotherapy
2
2015
201
0.050
 Why?
DNA Mismatch Repair
1
2023
50
0.050
 Why?
Information Seeking Behavior
1
2023
33
0.050
 Why?
Aromatase
1
2023
32
0.050
 Why?
Needles
1
2023
59
0.050
 Why?
Time Factors
4
2020
6817
0.050
 Why?
Focus Groups
1
2025
512
0.050
 Why?
Receptors, Estrogen
2
2016
435
0.050
 Why?
Anthracyclines
1
2021
49
0.050
 Why?
Taxoids
1
2021
104
0.050
 Why?
Precision Medicine
1
2025
426
0.040
 Why?
Trastuzumab
1
2021
101
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
51
0.040
 Why?
Hospitals, University
1
2021
181
0.040
 Why?
Estrogens
1
2023
361
0.040
 Why?
Quinolines
1
2021
180
0.040
 Why?
Radiometry
1
2019
50
0.040
 Why?
Microsatellite Instability
1
2019
43
0.040
 Why?
Chemoradiotherapy, Adjuvant
1
2019
43
0.040
 Why?
Organ Sparing Treatments
1
2019
34
0.040
 Why?
Cervix Uteri
1
2019
49
0.040
 Why?
Papanicolaou Test
1
2019
42
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
95
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
36
0.040
 Why?
Guidelines as Topic
1
2020
277
0.040
 Why?
Papillomaviridae
1
2019
126
0.040
 Why?
India
1
2018
193
0.040
 Why?
Neoplasm Metastasis
1
2020
659
0.040
 Why?
United States Department of Veterans Affairs
1
2022
671
0.040
 Why?
PTEN Phosphohydrolase
1
2019
162
0.030
 Why?
Equipment Design
1
2019
526
0.030
 Why?
Vagina
1
2019
186
0.030
 Why?
Organs at Risk
1
2017
32
0.030
 Why?
Statistics, Nonparametric
1
2017
434
0.030
 Why?
Predictive Value of Tests
1
2021
2039
0.030
 Why?
Skin Ulcer
1
2015
14
0.030
 Why?
HLA-A2 Antigen
2
2005
48
0.030
 Why?
Abdominal Neoplasms
1
2015
39
0.030
 Why?
Thoracic Neoplasms
1
2015
37
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2021
807
0.030
 Why?
Societies, Medical
1
2019
820
0.030
 Why?
Reoperation
1
2017
569
0.030
 Why?
Fibrosis
1
2017
552
0.030
 Why?
Odds Ratio
1
2017
1063
0.030
 Why?
Clinical Decision-Making
1
2017
321
0.030
 Why?
Evidence-Based Medicine
1
2018
746
0.030
 Why?
Disease Progression
2
2015
2755
0.030
 Why?
Biopsy
1
2017
1132
0.030
 Why?
Confidence Intervals
1
2013
328
0.030
 Why?
Age Distribution
1
2013
391
0.020
 Why?
Sex Distribution
1
2013
378
0.020
 Why?
Membrane Proteins
1
2019
1167
0.020
 Why?
Skin
1
2017
751
0.020
 Why?
Clinical Trials as Topic
1
2017
1047
0.020
 Why?
Comorbidity
1
2017
1618
0.020
 Why?
Vinblastine
1
2011
71
0.020
 Why?
Receptors, Progesterone
1
2013
349
0.020
 Why?
Dacarbazine
1
2011
97
0.020
 Why?
Remission Induction
1
2011
287
0.020
 Why?
Surveys and Questionnaires
1
2023
5772
0.020
 Why?
Analysis of Variance
1
2013
1324
0.020
 Why?
Mass Screening
1
2019
1264
0.020
 Why?
Colorado
1
2020
4521
0.020
 Why?
Bleomycin
1
2011
247
0.020
 Why?
Doxorubicin
1
2011
368
0.020
 Why?
Algorithms
1
2017
1702
0.020
 Why?
Sex Factors
1
2013
2074
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2420
0.020
 Why?
Incidence
1
2013
2792
0.020
 Why?
Pregnancy
1
2019
6745
0.020
 Why?
Cytotoxicity Tests, Immunologic
1
2005
41
0.020
 Why?
Cytotoxicity, Immunologic
1
2005
225
0.010
 Why?
T-Lymphocytes, Cytotoxic
1
2005
173
0.010
 Why?
Cross-Sectional Studies
1
2015
5427
0.010
 Why?
Immunoconjugates
1
2005
116
0.010
 Why?
Leukocytes, Mononuclear
1
2005
558
0.010
 Why?
Interferon-gamma
1
2005
790
0.010
 Why?
CD8-Positive T-Lymphocytes
1
2005
917
0.010
 Why?
Cell Line, Tumor
1
2005
3420
0.010
 Why?
Child
1
2013
22037
0.010
 Why?
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (255) concept(s)
_
Co-Authors Expand Description
See all (48) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)